<DOC>
	<DOCNO>NCT02807233</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness IGF-1 control lanreotide Autogel ( ATG ) 120 mg extend dosing interval ( EDIs ) ( &gt; 4 week ) subject acromegaly daily clinical practice .</brief_summary>
	<brief_title>Lanreotide Autogel 120 mg Extended Dosing Intervals ( &gt; 4 Weeks ) Acromegalic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Men woman age â‰¥ 18 year Diagnosed acromegaly Receiving treatment ATG 120 mg extend dosing interval ( &gt; 4 week ) least six month study visit . Assay data ( blood GH IGF1 level ) immediately study visit ( perform least six month start treatment ) available . Able sign inform consent form study participation . Received radiation therapy treatment last six month . Active participation another clinical study . Physical mental disorder , investigator 's opinion , could affect ability sign inform consent form . Pregnancy breastfeed female patient . No data medical record treatment start date ATG 120 mg extend dose interval change schedule administration last six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>